Skip to main content
OpenTrials
Completed

NCT Number: NCT00025766

Angioplasty and Heart Stents to Treat Individuals With an Occluded Artery Following a Heart Attack

The purpose of this study is to evaluate arterial patency and left ventricular ejection fraction by examining angiographic data one year following a heart attack and treatment with late revascularization.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University Health Network - Toronto General Hospital

Toronto, Ontario, Canada

About this study

BACKGROUND:

The Occluded Artery Trial (OAT) is an international study with 3200 participants. Its goal is to determine if delayed mechanical reperfusion by means of percutaneous transluminal coronary angioplasty (PTCA) and stenting reduces death, heart attacks, and hospitalization in individuals with New York Heart Association (NYHA) Class IV heart failure and a persistently occluded infarct-related artery (IRA) 3 to 28 days following a heart attack. While left ventricular (LV) function improvement has been suggested as a benefit of late reperfusion, solid evidence to support this claim is lacking. Furthermore, while stenting has reduced reocclusion rates after total occlusion PTCA, the reocclusion rate after a recent heart attack is unknown.

DESIGN NARRATIVE:

This study is a substudy of OAT and will enroll 380 participants. The primary aims of the study include the following: 1) to compare long-term patency rates between the two treatment groups (conventional medical therapy or PTCA and stenting) by means of follow-up coronary angiography one year after enrollment; and 2) to compare the change in global LV ejection fraction between the two treatment groups utilizing baseline and follow-up contrast LV angiograms. Secondary aims include the following: 1) comparison of regional wall motion and LV volumes; 2) study of the effect of reocclusion and spontaneous recanalization on LV function; and 3) study of the effect of duration of occlusion on changes in LV function after Percutaneous Coronary Intervention (PCI). The substudy will be conducted at 21 OAT study sites. The Substudy Coordinating Center (SCC) is at the University of Alberta in Edmonton, Canada. The Data Coordinating Center (DCC) is at the Maryland Medical Research Institute, which is the DCC for the OAT study. The Angiographic Core Laboratory is at the University of British Columbia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has experienced a heart attack 3 to 28 days prior to study entry
  • Has a persistently occluded IRA

Treatment and study plan

PCI with stenting

Device

PCI with stenting of the occluded culprit infarct-related artery

Optimal Medical Therapy

Behavioral

Participants will receive optimal medical therapy.

Primary outcomes

  1. LV ejection fraction

    Time frame: 1 year

  2. Infarct-related artery patency (measured by contrast LV and coronary angiography)

    Time frame: 1 year

Secondary outcomes

  1. Comparison of regional wall motion and LV volumes

    Time frame: 1 year

  2. Effect of reocclusion and spontaneous recanalization on LV function

    Time frame: 1 year

  3. Effect of duration of occlusion on changes in LV function after PCI

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Official study title

TOSCA-2: An Angiographic Substudy (Ancillary) of the Occluded Artery Trial (OAT)

Acronym: TOSCA-2

Important dates

Study start
2001
Primary completion
2006
Study completion
2011
First posted
Oct 23, 2001
Registry last updated
Nov 27, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.